Amryt Pharma has reported better than expected revenues for the six months to the end of June as the company said it had achieved significant milestones in the first half of the year.
Revenues for the company's half year came to €6.18m, which it also reported an operating loss of €5.79m.
This included €0.13m of depreciation and amortisation, as well as €0.31m of non-cash share based payments.
Amryt said it continued to see strong progress across all its key commercial and development assets.
Sales of its Lojuxta drug - which treats a rare, life-threatening disorder that causes abnormally high levels of "bad" cholesterol - were up strongly.
"Revenues are ahead of our expectations and we now believe that the potential addressable market is larger than we originally anticipated," commented the company's CEO Joe Wiley.
"A major focus for us looking forward is opening up new, untapped territories covered by our licence agreement," he said.
"The company has achieved significant milestones in the first half of 2017 and we remain confident of continuing strong progress over the remainder of 2017 and into 2018," he added.
